Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centus Biotherapeutics Limited
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18 years or older
Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease
Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC
Existence of at least 1 measurable lesion by RECIST v1.1
Adequate hematological, renal and liver function
Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1
Life expectancy longer than 6 months
You may not be if
Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature
Any unresolved toxicities from prior systemic therapy
Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations
Previous dosing with vascular endothelial growth factor (VEGF) inhibitor
Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy
Use of prohibited concomitant medication
Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection
Fertile men or women of childbearing potential not using adequate contraception.
Clareo Health | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
